Accès ouvert
2025
conference-abstract
OpenAlex
Jinxing Lou, Yan Sun, Shuya Wang, F. C. Ma et autres
Abstract Background: Broad clinical application of CAR-T therapy has been constrained by several barriers: (1) prolonged manufacturing process (≥ 2 weeks), delaying critical treatment access; (2) single-target antigen escape, enabling tumor relapse; and (3) lymphodepletion (LD)-related toxicities, excluding medical fragile patients. To …
cn, us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Toya Nath Baral, Weihong Wang, Jia Yu, Huiyuan Tang et autres
Background Colorectal cancer (CRC) represents a major unmet clinical need. Cadherin-17 (CDH17) is expressed in the majority of CRC, associated with poor prognosis and reduced survival. In normal intestinal tissue, CDH17 is restricted to tight junctions, but its aberrant overexpression and altered …
us, cn
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
John J. Lee, Leo Ng, Jing Yu, Jia Yu et autres
Background PD-1, CTLA-4, and VEGF are validated clinical targets with complementary roles in suppressing anti-tumor immunity. PD-(L)1/VEGF and PD-(L)1/CTLA-4 bispecific antibodies show promising clinical benefits for certain solid tumors, and several on-going studies explore a tri-targeting multi-drug combination approach. Given the avidity …
us, cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Yan Sun, Haochen Yang, Qing Xu, XingYa Li et autres
Abstract Malignant mesothelioma (MM) is an aggressive and currently incurable cancer with limited therapeutic options. Due to the high expression of mesothelin in this cancer, anti‐PD‐1 nanobody‐armored mesothelin‐targeting CAR‐T (NAC‐T) cells are developed. Based on the enhanced anti‐tumor activity observed in preclinical …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Saisai Wang, Pingjing Zhang, Yan Sun, Yuan Fang et autres
Transposons, as non-viral vectors, provide an efficient and secure method for stable gene delivery and have been successfully applied in human gene therapies. The engineering of transposase has significantly improved the efficiency of various transposon systems, including chimeric antigen receptor (CAR)-T cell …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Menglin Ren, Xiaodie Wang, Jiangrui Chen, Yuanjian Xu et autres
Cryopreserved leukapheresis is a scalable source for Chimeric antigen receptor T (CAR-T) manufacturing, yet it remains understudied (18.3% of 349 studies, 2010-2024). Current challenges include that cryopreserved leukapheresis lacks a standardized preparation process and has a low level of automation. Systematic validation …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Su Chen, Yueyang Liu, Na Wei, Kexin Xiang et autres
Natural killer (NK) cell‑based immunotherapy has emerged as a transformative approach for cancer treatment However, its widespread clinical application faces several challenges, such as donor variability, limited scalability and functional heterogeneity of primary NK cells. Additionally, issues including in vivo persistence, resistance …
cn
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Yan Sun, Zhicai Lin, Yong Xia, Lijie Rong et autres
2534 Background: CAR-T cells face challenges in solid tumors, including weak in vivo proliferation, immunosuppressive tumor microenvironments (TME), and limited tumor infiltration. We firstly developed an innovative non-viral JL-Lightning-CAR-T fast process to enhance CAR-T stemness, in vivo expansion, and persistence. The autologous …
cn
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Toya Nath Baral, Jia Yu, Weihong Wang, Huiyuan Tang et autres
Abstract T cell engagers (TCEs) have recent approvals and great potential in the treatment of various diseases such as cancer and auto-immune diseases. The challenge of TCE in solid tumor is the therapeutic window due to limited tumor specific targets, and the …
cn
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Shuya Wang, Yan Sun, Hongfan Zhu, Zhicai Lin et autres
Abstract Background: CAR-T with high in vivo proliferation and long persistency could benefit hematologic malignancy patients with low relapse and long survival. Previous studies reveal that CAR-T stemness (T-stem) and exhaustion level are major determinants of CAR-T quality that contribute to clinical …
cn, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Zenghui Xu, Ruyue Wang, Yuanjian Xu, Rui Qiu et autres
Chimeric antigen receptor T (CAR-T) therapy holds promise for cancer treatment but faces challenges with using fresh patient cells, including manufacturing failures and logistical hurdles. Cryopreserved peripheral blood mononuclear cells (PBMCs) offer a potential solution, and while lentiviral processes have been reported …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Yan Sun, Yuan Fang, Xiaodie Wang, Qian Huang et autres
Background To date, the non-viral vector Chimeric Antigen Receptor (CAR) T cell preparation platform, exemplified by transposons, has demonstrated significant potential in tumor immunotherapy and yielded positive results in multiple clinical trials. Nonetheless, non-methylated CpG sequences within plasmid DNA can elicit an …
cn
(code pays fourni par la source)